News KalVista bags FDA approval for delayed oral HAE drug KalVista has brought the first oral, on-demand treatment for hereditary angioedema attacks to the US market.
News Charities call for shake-up in UK rare disease R&D LifeArc and Genetics Alliance UK have issued a call to the government to remove obstacles impeding R&D into rare diseases.
News Trump signs Medicaid-slashing budget into law Trump's One Big Beautiful Bill Act is signed into law, and commentators are gauging its impact on healthcare insurance coverage.
News J&J bids to extend prostate cancer uses for Akeega J&J is hoping the AMPLITUDE study results will make Akeega the first drug in the PARP inhibitor class for castration-sensitive prostate cancer.
News Pharma welcomes EU push to restore life sciences sector European pharma trade group EFPIA has said that a strategy launched by the EU to bolster the region's standing in life sciences is a "step forward."
News Summit climbs on rumour of $15bn AstraZeneca interest Is AstraZeneca about to join the ranks of pharma companies spending big bucks on PD(L)-1xVEGF bispecific antibodies for cancer?
R&D Treating the chronic diseases GLP-1s miss, with Laurent Auda... Prive Bio CEO Laurent Audaly spoke with pharmaphorum during the JP Morgan Healthcare conference, discussing GLP-1s in the cardiometabolic space.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
